Collaborate Disseminate
As scientists scramble to understand what the real-world implications are from the many novel mutations seen in Omicron, the new SARS-CoV-2 variant, both Pfizer and Moderna are racing to update their mRNA vaccines. Although it is still unknown how well… Continue reading mRNA vaccine makers are working on new Omicron-specific formulations
New follow-up data from Pfizer’s Phase 3 trial testing its mRNA COVID-19 vaccine in 12 to 15 year olds show robust efficacy up to four months after the two-dose protocol. The data reveals the vaccine is 100 percent effective at preventing symptomatic S… Continue reading Pfizer’s COVID vaccine remains 100% effective in kids after four months
Researchers at the University of Texas at Dallas have developed a new type of vaccine against urinary tract infections (UTIs) that has shown promise in tests in mice. The treatment uses a whole dead bacteria cell, wrapped in a protective cage, to trigg… Continue reading UTI vaccine uses caged and killed bacteria to trigger an immune response
US regulators have authorized a third COVID-19 vaccine booster dose for all adults over the age of 18. The new recommendations simplify the health advice and infectious disease expert Anthony Fauci urges boosters for all those who are six months beyond… Continue reading All US adults now eligible for third dose of COVID-19 vaccine
A new study published in the journal Science Translational Medicine is reporting the development of a novel mRNA-based vaccine designed to help resist tick bites. Preclinical tests in guinea pigs indicate the vaccine aids the immune system in recognizi… Continue reading New mRNA anti-tick vaccine may protect from more than just Lyme disease
New real-world data from the UK Health Security Agency has shown a third COVID-19 vaccine dose significantly boosts protection against symptomatic disease. The findings indicate a third dose will be vital in pushing back the growing wave of SARS-CoV-2 … Continue reading Real-world data finds 3rd COVID vaccine dose greatly boosts protection
A new study in The Lancet is offering the first peer-reviewed and published data on the efficacy of Covaxin, a COVID-19 vaccine developed in India. The vaccine was found to be 77.8 percent effective at preventing symptomatic COVID-19 in a large Phase 3… Continue reading India’s Covaxin COVID-19 vaccine 77.8% effective, Lancet study finds
UK researchers investigating a cohort of healthcare workers with a strange pre-existing resistance to SARS-CoV-2 infection have discovered a new antigen target for the next generation of COVID-19 vaccines. The researchers speculate the next wave of vac… Continue reading Next-gen supercharged COVID-19 vaccines may also target the common cold
A massive study comparing the real-world effectiveness of three COVID-19 vaccines over eight months has detected protection from infection may decline but protection from death holds strong. Tracking nearly 800,000 US Veterans, the study found Johnson … Continue reading Study compares decline in effectiveness of 3 COVID vaccines over time
It goes without saying that a lot of people are receiving the COVID-19 vaccine these days, and will continue to do so for some time. A new robot is designed to help streamline the process, by autonomously – and needle-lessly – vaccinating human patient… Continue reading Cobi robot autonomously performs needle-less vaccinations